Advertisement

Indian Journal of Clinical Biochemistry

, Volume 33, Issue 3, pp 273–281 | Cite as

Association of Metabolic Syndrome and Oxidative DNA Damage in HIV/AIDS Patients

  • Vaishali Kolgiri
  • Vidya Nagar
  • Vinayak Patil
Original Article

Abstract

HIV-infected adults may be likely to have metabolic syndrome (MS) at younger ages and in the absence of obesity compared with general population. In the present study, we determined prevalence of MS and its association with oxidative deoxy nucleic acid (DNA) damage in HIV-1 infected patients with different ART status. We used plasma level of the oxidized base, 8-hydroxy-2-deoxyguanosine (8-OHdG), as a biomarker of oxidative DNA damage. To measure plasma 8-OHdG we used 8-OHdG enzyme-linked, immunosorbent assay. The biomarkers of MS were insulin resistance, Cholesterol/HDL ratio, Waist circumference and Hypertension. MS and oxidative DNA damage were significantly higher in HIV-positive patients with second line ART and first line ART than ART-naive patients. In a logistic regression analysis, increased MS was positively associated with the increased DNA damage (OR: 29.68, 95%:13.47, CI: 65.40) P = 0.0001. ART plays a significant role in the development of MS and oxidative DNA damage in HIV-positive patients taking antiretroviral therapy. Awareness and knowledge of MS and DNA damage in HIV/AIDS patients may prove helpful to clinicians to manage non-AIDS diseases such as cardiovascular disease and cancer. To determine exact role of ART in induction of MS and DNA damage larger studies are warranted.

Keywords

DNA damage Human immunodeficiency virus (HIV) infection Insulin resistance Metabolic syndrome 8-OH-dG 

Notes

Acknowledgements

National AIDS Control Organisation (NACO) Delhi, Mumbai District AIDS Control Society (MDACS) Mumbai and ART Centre Sir J J Group of Hospitals Mumbai supported this study.

Compliance with Ethical Standards

Conflict of interest

All authors declared that there are no conflicts of interest in this manuscript.

References

  1. 1.
    Vajpayee M, Mohan T. Current practices in laboratory monitoring of HIV infection. Indian J Med Res. 2011;134:801–22.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Hernandez-Romieu AC, Garg S, Rosenberg Eli S, et al. Is diabetes prevalence higher among HIV-infected individuals compared with the general population? Evidence from MMP and NHANES 2009–2010. BMJ Open Diabetes Res Care. 2017;5:e000304.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Mbunkah HA, Meriki HD, Kukwah AT, et al. Prevalence of metabolic syndrome in human immunodeficiency virus-infected patients from the South-West region of Cameroon, using the adult treatment panel III criteria. Diabetol Metab Syndr. 2014;6:92.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Van der Valk M, Bisschop PH, Romijn JA, et al. Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS. 2001;15:2093–100.CrossRefPubMedGoogle Scholar
  5. 5.
    Ledergerber B, Furrer H, Rickenbach M, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV cohort study. Clin Infect Dis. 2007;45:111–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Rotger M, Gsponer T, Martinez R, et al. Impact of single nucleotide polymorphisms and of clinical risk factors on new-onset diabetes mellitus in HIV-infected individuals. Clin Infect Dis. 2010;51:1090–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Brown TT, Li X, Cole SR, Kingsley LA, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the multicenter AIDS cohort study. AIDS. 2005;19:1375–83.CrossRefPubMedGoogle Scholar
  8. 8.
    Idiculla J, Ravindra’n GD, D’Souza J, et al. Diabetes mellitus, insulin resistance, and metabolic syndrome in HIV-positive patients in South India. Int J Gen Med. 2011;4:73–8.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Gundurao Sreekantamurthy G, Singh NB, Singh Th Bhimo, et al. Study of body composition and metabolic parameters in HIV-1male patients. J Nutr Metab. 2014;498497:5.Google Scholar
  10. 10.
    Krishnan S, Schouten JT, Atkinson B, et al. Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naïve HIV-infected individuals. J Acquir Immune Defic Syndr. 2012;61:381–9.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Jantarapakde J, Phanuphak N, Chaturawit C, et al. Prevalence of metabolic syndrome among antiretroviral-naive and antiretroviral-experienced HIV-1 infected Thai adults. AIDS Patient Care STDS. 2014;28:331–40.CrossRefPubMedGoogle Scholar
  12. 12.
    Tesfaye DY, Kinde S, Medhin G, Megerssa YC, et al. Burden of metabolic syndrome among HIV-infected patients in Southern Ethiopia. Diabetes Metab Syndr. 2014;8:102–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Kagaruki GB, Mayige MT, Ngadaya ES, et al. Magnitude and risk factors of non-communicable diseases among people living with HIV in Tanzania: a cross sectional study from Mbeya and Dar es Salaam regions. BMC Public Health. 2014;14:904.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Dalle-Donne I, Rossi R, Colombo R, et al. Biomarkers of oxidative damage in human disease. Clin Chem. 2006;52:601–23.CrossRefPubMedGoogle Scholar
  15. 15.
    Kryston TB, Georgiev AB, Pissis P, et al. Role of oxidative stress and DNA damage in human carcinogenesis. Mutat Res. 2011;711:193–201.CrossRefPubMedGoogle Scholar
  16. 16.
    Valavanidis A, Vlachogianni T, Fiotakis C, et al. 8-hydroxy-2′ -deoxyguanosine (8-OHdG): a critical biomarker of oxidative stress and carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2009;27(2):120–39.CrossRefPubMedGoogle Scholar
  17. 17.
    Katsuki A, Sumida Y, Gabazza EC, et al. Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes Care. 2001;24:362–5.CrossRefPubMedGoogle Scholar
  18. 18.
    Arama V, Tiliscan C, Streinu-Cercel A, et al. Insulin resistance and adipokines serum levels in a caucasian cohort of HIV-positive patients undergoing antiretroviral therapy: a cross sectional study. BMC Endocr Disord. 2013;13:4–6.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Serraino D, Bruzzone S, Zucchetto A, et al. Elevated risks of death for diabetes mellitus and cardiovascular diseases in Italian AIDS cases. AIDS Res Therapy. 2010;7:11.CrossRefGoogle Scholar
  20. 20.
    Capeau J, Bouteloup V, et al. Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. AIDS. 2012;26:303–14.CrossRefPubMedGoogle Scholar
  21. 21.
    Tangvarasittichai S. Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. World J Diabetes. 2015;6:456–80.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Kitazawa T, Yoshino Y, Suzuki S, et al. Lopinavir inhibits insulin signaling by promoting protein tyrosine phosphatase 1b expression. Exp Ther Med. 2014;8:851–5.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Butt AA, McGinnis K, et al. HIV infection and the risk of diabetes mellitus. AIDS. 2009;23:1227–34.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Ndona MM, Longo-Mbenza B, et al. Nadir CD4+, religion, antiretroviral therapy, incidence of type 2 diabetes mellitus, and increasing rates of obesity among black Africans with HIV disease. Int J Gen Med. 2012;5:983–90.Google Scholar
  25. 25.
    Tripathi A, Liese AD, Jerrell JM, et al. Incidence of diabetes mellitus in a population-based cohort of HIV-infected and non-HIV-infected persons: the impact of clinical and therapeutic factors over time. Diabet Med. 2014;31:1185–93.CrossRefPubMedGoogle Scholar
  26. 26.
    Arama V, Tiliscan C, Streinu-Cercel A, et al. Insulin resistance and adipokines serum levels in a Caucasian cohort of HIV-positive patients undergoing antiretroviral therapy: a cross sectional study. BMC Endocr Disord. 2013;13:4.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Mondy KE, de Las Fuentes L, Waggoner A, et al. Insulin resistance predicts endothelial dysfunction and cardiovascular risk in HIV-infected persons on long-term highly active antiretroviral therapy. AIDS. 2008;22:849–56.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Ben-Romano R, Rudich A, et al. Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors. AIDS. 2003;17:23–32.CrossRefPubMedGoogle Scholar

Copyright information

© Association of Clinical Biochemists of India 2017

Authors and Affiliations

  1. 1.Department of Biochemistry and MedicineGrant Government Medical College and Sir J J Groups of HospitalsMumbaiIndia

Personalised recommendations